BioCentury | Nov 25, 2020
Product Development

Friedreich’s ataxia program hits FDA snag, denting Reata’s shares

FDA’s conclusion about data Reata added to a potentially registrational package for its Friedreich’s ataxia program sliced about $420 million from the company’s market cap, and could complicate the therapy’s path to U.S. approval. The...
BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors....
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

This story was updated to correct the nature of Imperial College's deal with the U.K. As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi...
BioCentury | Jul 17, 2020
Product Development

Vaccine developments in China include IND acceptance for Fosun, Phase II start for Chongqing Zhifei

Two days after FDA granted Fast Track designation to two of BioNTech’s partnered COVID-19 vaccine candidates, one of the products advanced closer to human testing in China. Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196)...
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

Master protocols for COVID-19 clinical trials are testing half a dozen molecules that aim to prevent respiratory distress in patients with severe disease by targeting the host immune system -- four of these compounds intervene...
BioCentury | Apr 11, 2020
Translation in Brief

ILIAS Biologics’ exosomes for sepsis; plus regulating cocaine seeking and a new COVID-19 target

Relieving sepsis-related organ damage An ILIAS Biologics Inc. and Korea Advanced Institute of Science and Technology team described in Science Advances a sepsis treatment comprising exosomes loaded with a “super repressor” NF-κB inhibitor: a dominant...
BioCentury | Mar 14, 2020
Translation in Brief

A peptide fusion blocker for multiple coronaviruses, the cryo-EM structure of SARS-CoV-2 main protease, plus Locus, Excision and Harvard-Dana-Farber

Fudan University develops pan-coronavirus inhibitor A team led by Fudan University researchers has developed a lipopeptide-based pan-coronavirus inhibitor of viral membrane fusion. Described in a preprint on the bioRxiv server, the lipopeptide binds the SARS-CoV-2...
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

A trio of Weill Cornell and Sloan Kettering researchers have launched Volastra with $12 million in seed funding to develop therapies targeting chromosomal instability -- a driver of cancer metastasis. Polaris Partners led the seed...
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University team identifies colitis-associated somatic mutations that are lost in colitis-associated cancer to reveal a new colorectal cancer target. A Japanese team has identified novel colorectal cancer targets by contrasting somatic mutations in cancerous...
Items per page:
1 - 10 of 271